HIV TREATMENT
2020
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Continue to host the Paediatric ARV Drug Optimization (PADO) process and update the list of priority products with a view to providing a consistent, clear, and harmonized set of products that will be communicated to industry and regulators in a timely manner, and ensure inclusion of PADO priority products in the WHO Expression of Interest list as soon as dosing is provided.
World Health Organization (WHO)
Continue to host the PADO process
WHO
WHO convened a virtual meeting of the Pediatric ARV Drug Optimization (PADO) group in December 2017 to review the list of PADO3 pediatric ARV formulations and develop implementation considerations related to current priority products.
list of priority paediatric ARV formulations
A summary report on the PADO3 review (held December, 12 2017) was sent to representatives from pharmaceutical companies and to PADO members which include key stakeholders, regulators and key funders. The meeting report is available for dissemination (see document PADO3 review summary).
http://www.who.int/hiv/pub/meetingreports/pado3-review/en/
PADO 4 is planned for December 10th to 12th 2018.
Sub-action ongoing
One meeting is held in 2018
WHO
-
Communications of the meetings are shared with stakeholders.
WHO
Two webinars were held on Feb 5th by ILF/IAS in collaboration with WHO to disseminate the key outcomes of the PADO3 review to manufacturers and key stakeholder. Recordings and slides from webinars are available from ILF/IAS - http://www.iasociety.org/HIV-Programmes/Programmes/Industry-Liaison-Forum/Events/ILF-Webinar-Report-back-on-PADO-3-review . A summary report on the PADO3 review (held December, 12 2017) was sent to representatives from pharmaceutical companies and to PADO members which include key stakeholders, regulators and key funders. The meeting report is available for dissemination (see document PADO3 review summary)
Milestone completed
-
Update list of priority products, ensuring the list is consistent, clear and harmonized
WHO
-
-
The list of priority products is reviewed once in 2018
WHO
The EML will be updated by the end of 2018.
-
Communicate to industries and regulators in timely manner
WHO
WHO shared the PADO 3 Review Summary Report with industry and regulators on first March 18.
A webinar for dissemination to industry and regulators is scheduled for the week of Dec 19th 2018
-
-
-
-
-
-
-
-
-
Sub-Actions & Milestones
Responsible
Notes
Updates
This meeting is scheduled to take place in Q3 - dates to be confirmed by WHO staff.
Ensure inclusion of PADO priority products in the WHO Expression of Interest list as soon as dosing is provided.
WHO
-
-
-
-
-
-